Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This is undervalued should move up 50% this afternoon
Could hardly be better, SP heading back into 40's
Signs transformational US collaboration with Almirall's aesthetics subsidiary Thermi, completion of strategic review, end of offer period and provides positive trading update · Transformational US distribution and strategic marketing agreement with Thermi for Silhouette InstaLift™ delivers immediate access through 55 sales reps to the world's largest aesthetics market o Complements Thermi's existing minimally invasive aesthetics portfolio o Established US installed base of more than 1,000 Thermi systems · Creation of Brazilian affiliate to sell Silhouette Soft® is immediately earnings enhancing and provides a platform for future product launches in this top five global aesthetic market · Current trading remains strong; o Jan-Mar 2016 sales £8.9 million (compared to £7.7million in six months to 31 Dec 2015) o Sinclair continues to expect to deliver 40% revenue growth in calendar 2016 · Strategic review completed and end of offer period · Change of year end to 31 December
interest in this stock is finally picking up and I'm not at all surprised. IMO this is just the beginning.
Highlights - Created a focused and dedicated international aesthetics company with fast growth, a unique portfolio and a transformational opportunity in the US o US launch of Silhouette InstaLift™ on track for Q4 FY16 - As expected, reported sales at £7.7 million (H1 FY15: £10.5 million) were lower in H1 as a result of planned distributor de-stocking - Overall in-market growth rate of 31% for the 6 month period to 31 December 2015 o Ellansé® in-market sales +100% o Silhouette + 64% - Pre-launch activities for Silhouette InstaLift™ increased during the period and the initial reception has exceeded Company expectations - Disposal of non-aesthetics business for £132 million has strengthened the balance sheet which is now debt free - Net cash of £75.4 million at 31 December 2015 available to invest in future growth opportunities - The Company remains in an offer period
The more I read the latest accounts and look at the main shareholders, the more I think that this could be packaged by institutional holders (Toscafund etc) for a sale of all assets and related value maximization for the shareholders. Do other long term holders have the same feeling ?
60,000 of these as I looked into it on the back of an article in the 'Shares' magazine which not only confirms the net of cash £ 80mio + position but the fact that the company is left with no debt and the higher quality aesthetic business and that the company is still in an offer period and in their view they might sell also the other assets at a valuation significantly higher than current prices. No one knows if this will be the case but even if they keep the business left the company looks interesting for other possible interaction solutions with a number of international companies as per page 5 of their latest annual account. In addition Silhouette should be launched in q2 2016 in the US which could be another catalyst. Time to sit back now and see how matters turn out.
Sinclair IS Pharma (SPH LN): First Stab at Re-focused Entity: It's a Beauty; Boosting PT to 60p Rating BUY Price Target 60.00p (from 45.00p) Price 37.75p Key Takeaway Disposing of all products outside aesthetic dermatology leaves a more focused company with a leaner structure and improved growth trajectory. The attractive deal terms, in our view, boost the PT +33% to 60p. Importantly the Board's Nov '14 strategic review is still ongoing, with the new entity potentially a more attractive target for suitors. Pro-forma on 9x and 6x EV/Adj-EBITDA FY2017-18E with a c.40+% EPS CAGR, valuation remains attractive, hence our Buy. Executing aesthetic derm focus: Sinclair has disposed of all its products outside aesthetic dermatology to Alliance Pharma for £132m cash; an attractive valuation given recent sales pressures and somewhat fragmented portfolio, in our view. Key benefits beyond greater focus include: (1) simplified corporate structure; (2) debt facility repaid for pro-forma Net Cash c.£82m; and (3) improved sales growth trajectory. Aesthetic products performed strongly in FY15 at +35% LfL despite inventory destocking and S Korea headwinds. These challenges have been addressed but re-basing inventories will likely curtail FY16E sales, with +8-25% LfL targeted (JEFe +18%) from c.+40% in-market performance. Strategic review ongoing: There was no update on the Board's progress but a number of parties are still in discussions. We believe the new leaner, focused entity is likely to be more attractive for potential suitors, being easier to integrate and value. Hiking PT +33% to 60p: Our higher PT largely reflects the attractive deal terms for the disposal. Pro-forma 60p/share suggests an EV around £215m implying 4.2x and 3.4x Revenues, or 19x and 13x EBITDA, in FY17E and FY18E, respectively, which we view to be still relatively conservative. Attractive growth profile: We see a strong strategic rationale in focusing on a portfolio of dermal fillers, in addition to Silhouette for minimally invasive face-lifts. These brands form a unique aesthetic dermatology franchise, in our view, which with targeted S&M efforts should drive substantial operating leverage with the promise of long product lifecycles. Valuation/Risks Our 60p per share Price Target is derived by applying an equal weight to our DCF and a blended FY2021E multiple, capturing both the long-term trends and the context of the sector, in our view. Risks: (1) execution risk around marketing key brands and cost control; (2) slower emerging market growth; and (3) pipeline disappointments.
The Independent Jamie Nimmo On the junior market, Alliance Pharma, which licenses approved drugs that the major drug makers no longer want, dipped 5.25p to 45.75p after striking a deal to buy the dermatology business of Sinclair IS Pharma, which put on 2p at 37.75p.
Elixir of youth renews Sinclair as it announces sale of medical dermatology business to Alliance Pharma for £127.5m By GEOFF FOSTER FOR THE DAILY MAIL PUBLISHED: 22:07, 26 November 2015
By Tara Cunningham, Business Reporter6:41PM GMT 26 Nov 2015 Aim-listed Sinclair Pharma ticked 5.6pc higher to 37.8p after the group revealed it would dispose of its medicinal dermatology business for £136m. The pharmaceutical firm said it will use the proceeds to invest in its aesthetics products business.
I really like what we heard to-day! CEO Chris Spooner said "Today we have announced the disposal of our non-aesthetics business for an upfront cash consideration of c.£132m to create a fast growing and high gross margin pure-play aesthetics company with a leading and differentiated position in collagen stimulation. In-market sales data shows that the growth rate of our Aesthetics portfolio has accelerated throughout 2015 and is now trending at c.40%. The disposal substantially reduces business complexity and transforms Sinclair's balance sheet. The Company remains in an offer period as a result of continued interest in Sinclair's leading aesthetics brands" Very exciting all round!
Pfizer/Allergan....Lupin/Sinclair?
Anyone notice the buyer of 6.2m shares at 37.5 on the order book? Perhaps a vote of confidence.
Seems this stock is becoming quite Bullish and possibly a huge money maker :)
After all - £400 million or more is nothing in this very special and remunerative market for someone who needs greater entry into Europe, USA and Russia plus in a very much expanding area of growth
In view of their place in competition with Botox etc etc I am hoping that we might be looking for 74p plus when all the possible suitors are brought out into the open.
I think sph will be offered 55p takeover tops any thoughts?
3 month Sp high 48p, so would be good to see if SPH tests that area....
Can't buy atm, looks like MMs moping sells and buys going NT...
Looks like further to climb up if deal is announced...
http://www.financialwisdomworks.com/analysts-set-sinclair-is-pharma-plc-price-target-at-41-86-lonsph/18756/ "Analysts Set Sinclair IS Pharma PLC Price Target at $41.86 (LON:SPH)"
"hares of Sinclair IS Pharma PLC (LON:SPH) have been given an average rating of “Hold” by the eight ratings firms that are currently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is GBX 41.86 ($0.64). "